Mostrando 6 resultados de: 6
Filtros aplicados
Publisher
American Journal of Therapeutics(3)
Revista Latinoamericana de Hipertension(2)
Archivos Venezolanos de Farmacologia y Terapeutica(1)
Área temáticas
Enfermedades(4)
Salud y seguridad personal(2)
Bioquímica(1)
Grupos de personas(1)
Medicina y salud(1)
Exploratory study of the behavior of lipidic profile, malondialdehyde and nitric oxide in individuals of the Yukpa ethnic group from Zulian state, Venezuela
ArticleAbstract: Introduction: an abnormal lipidic profile is a risk indicator for cardiovascular diseases associatedPalabras claves:cardiovascular diseases, HDL, Lipidic profile, Malondialdehyde, Nitric oxideAutores:Acosta L., Amell A., Cano-Ponce C., Colmenares C., González M.C., Medina M.T., Nuñez M., Perez A., Rincón L., Seyfi H.A., Souki-Rincón A., Urribarri J., Valmore Bermúdez, Viloria A.Fuentes:scopusEffect of cigarette smoking on the oxidant/antioxidant balance in healthy subjects
Conference ObjectAbstract: BACKGROUND AND PURPOSE: Cigarette smoking has been associated with the development of cardiovascularPalabras claves:Ascorbic acid, Cigarette smoking, Glutathione, Malondialdehyde, Nitric oxide, Vitamin CAutores:Amell A., Cano R.A., Cano-Ponce C., Chávez J., Ciszek A., Contreras F., Hernández-Hernandez R., Israili Z.H., Medina M.T., Reyna-Villasmil N., Souki-Rincón A., Suárez G., Toledo A., Valasco M., Valmore Bermúdez, Vargas M.E.Fuentes:scopusPharmacologic management of isolated low high-density lipoprotein syndrome
ArticleAbstract: High-density lipoprotein (HDL) cholesterol is a heterogeneous group of lipoproteins exhibiting a varPalabras claves:atherosclerosis, cholesterol, Coronary artery disease, dyslipidemia, HDLc, Reverse cholesterol transportAutores:Acosta L., Amell A., Arráiz N., Bermúdez F.A., Cano R.A., Cano-Ponce C., Finol F., Hernández-Hernandez R., Hidalgo J., Kendall P., Manuel V., Pabón M.R., Reyna-Villasmil N., Valmore BermúdezFuentes:scopusPharmacologic treatment of obesity: Present, past and future
ReviewAbstract: Obesity is a chronic, stigmatized and costly disease that is rarely curable and is increasing in prePalabras claves:body mass index, Energetic balance, Noradrenegic agents, obesity, Orlistat, Serotoninergic agents, SibutraminAutores:Amell A., Bermúdez F.A., Cabrera M., Leal E.M., Mengual-Moreno E., Rodriguez M., Silva C., Toledo A., Valdelamar L., Valmore BermúdezFuentes:scopusLipoprotein(a): From molecules to therapeutics
ReviewAbstract: Lipoprotein (a) [Lp(a)] was discovered by Kare Berg in 1963 from the study of low-density lipoproteiPalabras claves:Atherogenesis, Cardiovascular disease, Hyperlipoproteinemia(a), lipoprotein(a), therapeuticsAutores:Amell A., Aparicio D., Arráiz N., Cabrera M., Canelón R., Cano R.A., Cano-Ponce C., Faria J., Gotera D., Guerra-Torres X.E., Mengual-Moreno E., Reyna-Villasmil N., Rojas E.R., Sorell L.T., Valmore Bermúdez, Velasco M.Fuentes:scopusSerum lipoprotein (a) in patients post myocardial infarction
ArticleAbstract: Lipoprotein (a) [Lp (a)] is considered an independent risk factor for cardiovascular disease. In ourPalabras claves:Abdominal circumference, body mass index, dyslipidemia, Lipoprotein (a), myocardial infarctionAutores:Amell A., Añez-Ramos R., Arráiz N., Cano-Ponce C., Carem Prieto, Carrillo M., Cruz S., González M.C., Joselyn Zula, Montiel M., Salazar-Vílchez J., Silva C., Toledo A.C., Torres Y., Valmore Bermúdez, Vergara P.M.Fuentes:googlescopus